Covid-19. COVID-19 Disease
Conditions
Interventions
Intervention 1: Intervention group: In addition to the standard treatment regimen forCOVID-19, the minocycline capsule 100 mg will be given two times a day for 2 weeks. Intervention 2: Control group:
Sponsors
Mashhad University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: Patients with covid-19 symptoms Indication of home quarantine and outpatient medication; Age range 18 to 65
Exclusion criteria
Exclusion criteria: Patients connected to a catheter Patients under chemotherapy Patients taking cytotoxic drugs or corticosteroids Pregnant and lactating patients Patients with severe renal insufficiency Patients with liver failure Diabetic patients
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Time interval until clinical symptoms improve. Timepoint: 3 days, 1 week and 2 weeks after treatment. Method of measurement: time of recovery. | — |
Secondary
| Measure | Time frame |
|---|---|
| Fever. Timepoint: 3 days, 1 week and 2 weeks after treatment. Method of measurement: Thermometer.;Lymphopenia. Timepoint: 3 days, 1 week and 2 weeks after treatment. Method of measurement: Cell counter device.;CRP. Timepoint: 3 days, 1 week and 2 weeks after treatment. Method of measurement: CRP kit. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactHossein Hosseinzadeh
Mashhad University of Medical Sciences
Outcome results
None listed